2.26

1.74% -0.04

After Hours: 2.28 0.02 +0.88%

Perspective Therapeutics Inc (CATX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Perspective Therapeutics Inc stock is traded at $2.26, with a volume of 966.30K. It is down -1.74% in the last 24 hours and down -23.65% over the past month. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Previous Close:

$2.30

Open:

$2.25

24h Volume:

966.30K

Relative Volume:

0.78

Market Cap:

$257.98M

Revenue:

$618.00K

Net Income/Loss:

$-111.65M

P/E Ratio:

-1.6189

EPS:

-1.396

Net Cash Flow:

$-107.53M

1W Performance:

-3.42%

1M Performance:

-23.65%

6M Performance:

-52.02%

1Y Performance:

-24.92%

1-Day Range:

$2.22

$2.335

1-Week Range:

$2.15

$2.37

52-Week Range:

$1.955

$6.16

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name

Perspective Therapeutics Inc

Sector

Healthcare (1051)

Industry

Medical Devices (142)

Phone

509-375-1202

Address

350 Hills Street, Suite 106, Richland

Employee

166

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

CATX's Discussions on Twitter

Compare CATX vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CATX Perspective Therapeutics Inc	2.26	257.98M	618.00K	-111.65M	-107.53M	-1.396
ABT Abbott Laboratories	102.51	177.38B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	96.59	123.55B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	307.08	117.79B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	46.01	66.68B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.09	51.93B	6.30B	1.07B	1.09B	1.8406

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-26	Initiated	William Blair	Outperform
Aug-19-26	Initiated	BMO Capital Markets	Outperform
Feb-19-26	Initiated	Piper Sandler	Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-10-25	Initiated	BTIG Research	Buy
Mar-13-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-01-24	Initiated	Wedbush	Outperform
Sep-25-24	Initiated	Truist	Buy
Jul-25-24	Initiated	BofA Securities	Buy
May-09-24	Initiated	Cantor Fitzgerald	Overweight

View All

Perspective Therapeutics Inc Stock (CATX) Latest News

Oct 20, 2026

Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail

Oct 20, 2026

Oct 17, 2026

Perspective Therapeutics, Inc. (AAJ0.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Oct 17, 2026

Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia

Oct 17, 2026

Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Oct 17, 2026

Oct 14, 2026

Perspective Therapeutics (CATX) Receives a Buy from Wedbush - The Globe and Mail

Oct 14, 2026

Oct 13, 2026

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $11 - Moomoo

Oct 13, 2026

Oct 09, 2026

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Zacks Investment Research

Oct 09, 2026

Oct 08, 2026

With treatment options limited, a tumor therapy gets FDA Fast Track at Perspective Therapeutics (CATX). - Stock Titan

Oct 08, 2026

Perspective Therapeutics Granted Fast Track Designation for - GlobeNewswire

Oct 08, 2026

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors - Yahoo Finance

Oct 08, 2026

Oct 07, 2026

Perspective Therapeutics, Inc. (AAJ0.F) stock price, news, quote and history - Yahoo Finance UK

Oct 07, 2026

Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors - Quiver Quantitative

Oct 07, 2026

Cancer-treatment data will get an oral presentation at a November medical symposium. - Stock Titan

Oct 07, 2026

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium - GlobeNewswire

Oct 07, 2026

Oct 04, 2026

UBS Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Oct 04, 2026

Oct 02, 2026